ECU
BMRN icon

Eisler Capital (UK)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Eisler Capital (UK)’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,401
Closed -$384K – 500
2024
Q1 		$384K Sell
4,401
-8,183
-65% -$733K ﹤0.01% 573
2023
Q4 		$1.21M Buy
+12,584
New +$1.11M 0.01% 475

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Eisler Capital (UK)'s BMRN Position: Q2 2024 in Review

Eisler Capital (UK) sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 4,401 shares — an estimated $384K sold.

Eisler Capital (UK) first reported a position in BMRN in Q4 2023 and held it in 2 quarters. The position peaked at $1.21M in Q4 2023. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

  • Eisler Capital (UK) reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Eisler Capital (UK) sold 4,401 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $384K.
  • Eisler Capital (UK) first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Eisler Capital (UK)'s BioMarin Pharmaceuticals position peaked at $1.21M in Q4 2023.
  • 558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Eisler Capital (UK)'s 13F filing for Q2 2024, filed 13 Aug 2024.